Xcenda and National Pharmaceutical Council Publish New White Paper on Payer and Provider Desire for More Data and Evidence
August 31, 2017
With the introduction of Section 114 of the Food and Drug Administration Modernization Act (FDAMA) in 1997, a pathway for communication of health care economic information (HCEI) between manufacturers and formulary and treatment decision-makers was established. A new white paper from Xcenda and the National Pharmaceutical Council (NPC) highlights survey findings from payers and providers on what types of evidence are most important to them when it comes to making population coverage decisions for formularies and care pathways.
Key insights from the survey include:
- Payers and providers desire for more information: Both payers and providers value having several types of information available when making decisions; however, few of these types of information are typically available on a product's FDA-approved label.
- Decision-making is limited by the available information: Both payers and providers felt limited in the resources available to them to make decisions.
- Weighing potential benefits and harms of more information: Payers and providers agreed that benefits appear to outweigh potential harms when it comes to more information.